Recce Pharmaceuticals Ltd. announced it completed dosing healthy subjects in the latest cohort of its Phase I/II trial, evaluating its lead candidate, RECCE® 327 (R327), at fast infusion rates. An Independent Safety Committee will now review and evaluate the comprehensive data from the 4-subject cohort. Recruitment for the next cohort is underway.

Data from this trial is expected to pave the way for a Phase II trial to establish the potential of R327 as a frontline treatment for patients with UTIs or urosepsis. The administration of antibiotics via rapid intravenous infusions is a proven safe and effective method of administration, impacting patient treatment, wait times, and nursing workloads globally.